Abstract
Bacillus licheniformis α-amylase (BLA) is routinely used as a model thermostable amylase in biochemical studies. Its starch hydrolysis activity has recently been studied in Tris buffer. Here, we address the question that whether the application of Tris buffer may influence the results of BLA activity analyses. Based on the inhibition studies and docking simulations, we suggest that Tris molecule is a competitive inhibitor of starch-hydrolyzing activity of BLA, and it has a high tendency to bind the enzyme active site. Hence, it is critically important to consider such effect when interpreting the results of activity studies of this enzyme in Tris buffer.
Keywords: BLA, Tris inhibition, buffer inhibition, activity, docking, French bean, glucuronic acid, lectin, mitogenic activity, HepG2, breast cancer, glycoproteins, N-acetylgalactosamine-binding, polysaccharides, inflammation,, thrombosis, metastasis, Phaseolus vulgaris, AKTA Purifier, PBS, SDS-PAGE, HPLC, MCF7, CNE1, CNE2, MTT, Affi-gel blue gel, FPLC, hemagglutinating, N-acetylglucosamine, Aprotinin, Ovalbumin, Temperature, CNE, PHAs, ATP, Con A, chromatography, gel filtration, anti-HIV reverse transcriptase
Protein & Peptide Letters
Title: Binding of Tris to Bacillus licheniformis α-Amylase Can Affect Its Starch Hydrolysis Activity
Volume: 15 Issue: 2
Author(s): Zahra Ghalanbor, Nasser Ghaemi, Sayed-Amir Marashi, Massoud Amanlou, Mehran Habibi-Rezaei, Khosro Khajeh, Bijan Ranjbar, Yau Sang Chan, Jack Ho Wong and Tzi Bun Ng
Affiliation:
Keywords: BLA, Tris inhibition, buffer inhibition, activity, docking, French bean, glucuronic acid, lectin, mitogenic activity, HepG2, breast cancer, glycoproteins, N-acetylgalactosamine-binding, polysaccharides, inflammation,, thrombosis, metastasis, Phaseolus vulgaris, AKTA Purifier, PBS, SDS-PAGE, HPLC, MCF7, CNE1, CNE2, MTT, Affi-gel blue gel, FPLC, hemagglutinating, N-acetylglucosamine, Aprotinin, Ovalbumin, Temperature, CNE, PHAs, ATP, Con A, chromatography, gel filtration, anti-HIV reverse transcriptase
Abstract: Bacillus licheniformis α-amylase (BLA) is routinely used as a model thermostable amylase in biochemical studies. Its starch hydrolysis activity has recently been studied in Tris buffer. Here, we address the question that whether the application of Tris buffer may influence the results of BLA activity analyses. Based on the inhibition studies and docking simulations, we suggest that Tris molecule is a competitive inhibitor of starch-hydrolyzing activity of BLA, and it has a high tendency to bind the enzyme active site. Hence, it is critically important to consider such effect when interpreting the results of activity studies of this enzyme in Tris buffer.
Export Options
About this article
Cite this article as:
Ghalanbor Zahra, Ghaemi Nasser, Marashi Sayed-Amir, Amanlou Massoud, Habibi-Rezaei Mehran, Khajeh Khosro, Ranjbar Bijan, Sang Chan Yau, Ho Wong Jack and Bun Ng Tzi, Binding of Tris to Bacillus licheniformis α-Amylase Can Affect Its Starch Hydrolysis Activity, Protein & Peptide Letters 2008; 15 (2) . https://dx.doi.org/10.2174/092986608783489616
DOI https://dx.doi.org/10.2174/092986608783489616 |
Print ISSN 0929-8665 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5305 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Hijacking the Hedgehog Pathway in Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry Targeting Steroid Hormone Receptor Pathways in the Treatment of Hormone Dependent Cancers
Current Pharmaceutical Biotechnology Targeting the Immune System in Cancer
Current Pharmaceutical Biotechnology The Renin Angiotensin System in the Regulation of Angiogenesis
Current Pharmaceutical Design Editorial: [Recent Advances in Mammography]
Recent Patents on Medical Imaging The Use of the Zebrafish Model to Aid in Drug Discovery and Target Validation
Current Topics in Medicinal Chemistry Therapeutic Use of Brentuximab Vedotin in CD30+ Hematologic Malignancies
Anti-Cancer Agents in Medicinal Chemistry Phase II Drug Metabolism and Individualized Drug Therapy: A Focus on Functional Genetic Variation in UDP-Glucuronosyltransferases
Current Pharmacogenomics and Personalized Medicine Estrogens and Progression of Diabetic Kidney Damage
Current Diabetes Reviews Antineoplastic and Antimicrobial Potential of Novel Phytofabricated Silver Nanoparticles from <i>Pterospermum acerifolium</i> Leaf Extract
Nanoscience & Nanotechnology-Asia Application of Phage Display Technology to Cancer Research
Current Pharmaceutical Biotechnology Advances in the Systemic Treatment of Neuroendocrine Tumors in the Era of Molecular Therapy
Anti-Cancer Agents in Medicinal Chemistry Challenges and Opportunities from Basic Cancer Biology for Nanomedicine for Targeted Drug Delivery
Current Cancer Drug Targets Natural Products as Anti-Invasive and Anti-Metastatic Agents
Current Medicinal Chemistry Recent Updates of N-Type Calcium Channel Blockers with Therapeutic Potential for Neuropathic Pain and Stroke
Current Topics in Medicinal Chemistry Adrenoceptors: Non Conventional Target for Breast Cancer?
Current Medicinal Chemistry Anti-Cancer/Anti-Tumor
Current Bioactive Compounds Autophagy Inhibits Apoptosis Induced by agrocybe aegerita Lectin in Hepatocellular Carcinoma
Anti-Cancer Agents in Medicinal Chemistry Fatty Acid Synthase: A Target for the Reversal of Liver Steatosis
Current Enzyme Inhibition Mechanisms of Drug-Induced Mitotic Catastrophe in Cancer Cells
Current Pharmaceutical Design